ALK-Rearranged Non-SmallCell Lung Cancer in 2020:Real-WorldTriumphs in an Era of MultigenerationALK-InhibitorSequencing Informed by Drug Resistance Profiling
Malinda Itchins, Brandon Lau, Amanda L Hudson, Helen Westman, Cathy Yi Xia, Sarah A Hayes, Viive M Howell, Michael Rodriguez, Wendy A Cooper, Heng Wei, Michael Buckland, Bob T Li, Mark Li, Vivek Rathi, Stephen B Fox, Anthony J Gill, Stephen J Clarke, Michael J Boyer, Nick Pavlakis
The Oncologist | WILEY | Published : 2020
Since its discovery in 2007, we have seen the lives of patients diagnosed with advanced anaplastic lymphoma kinase (ALK)-rearranged non-small cell lung cancers (NSCLC) transform with the advent of molecular therapies with first-, second-, and third-generation ALK inhibitors now available in the clinic. Despite great gains in patient survival now measured in years and preserved quality of life with targeted therapies, drug resistance is unfortunately inevitably encountered in this rare and unique molecular subset of lung cancer, and patients will eventually succumb to the disease. As these patients are often young, fit, and never smokers, the clinical and scientific communities have aligned t..View full abstract
Dr. Malinda Itchins is funded by an NSW Health PhD Scholarship, the Dwyer Family, and a Sydney Vital Scholar Award.